On Wednesday, Yingli Green Energy Hold. Co. Ltd. (ADR) (NYSE:YGE)’s shares declined -9.73% to $1.02.
Yingli Green Energy Hold. Co. Ltd. (ADR) (YGE) declared that it plans to release its unaudited financial results for the quarter ended March 31, 2015, before the U.S. market opens on Friday, June 5, 2015.
The Company has planned a corresponding conference call and live webcast to talk about the results at 8:00 AM U.S. Eastern Daylight Time on June 5, 2015, which corresponds to 8:00 PM Beijing/Hong Kong time on the same day.
Yingli Green Energy Holding Company Limited, together with its auxiliaries, designs, develops, manufacture, markets, sells, and installs photovoltaic products in the People’s Republic of China. It offers PV cells, PV modules, and integrated PV systems; and polysilicon ingots and blocks, and polysilicon wafers, in addition to develops and operates solar projects.
China Ming Yang Wind Power Group Ltd (NYSE:MY)’s shares dropped -8.29% to $3.21.
China Ming Yang Wind Power Group Ltd (MY) declared its unaudited financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Operating and Financial Highlights:
- For the quarter ended March 31, 2015, total wind turbine generators (“WTGs”) for which revenue was recognized amounted to an equivalent wind power project output of 406MW, or 100 units of 1.5MW WTGs and 128 units of 2.0MW WTGs.
- Total revenue was RMB1,334.9 million (US$215.3 million) contrast to RMB1,224.0 million in the first quarter of 2014.
- Among the revenue of RMB1,224.0 million in the first quarter of 2014, revenue of RMB321.1 million, representing WTGs with power output of 99MW, was recognized under the EPC arrangements. None of the WTGs commissioned in the first quarter of 2015 was under the EPC arrangements. As such, total revenue other than EPC arrangements raised by 47.8% in the first quarter of 2015 contrast to the corresponding period in 2014.
- Gross profit was RMB189.1 million (US$30.5 million), contrast to RMB192.0 million in the first quarter of 2014.
First Quarter 2015 Operating Data and Unaudited Financial Results
Revenue
Revenue in the first quarter of 2015 was RMB1,334.9 million (US$215.3 million) contrast to RMB1,224.0 million in the first quarter of 2014. Among the revenue of RMB1,224.0 million in the first quarter of 2014, revenue of RMB321.1 million was recognized under the EPC arrangements. As such, total revenue other than EPC arrangements raised by 47.8% in the first quarter of 2015 contrast to the corresponding period in 2014 of RMB902.9million. The enhance was due to the combined effect of (1)a 41.5% enhance in the number of WTGs commissioned (measured by power output) as mentioned below, and (2) more 2.0MW WTGs with higher selling price being commissioned in the first quarter of 2015 contrast with the corresponding period of 2014.
China Ming Yang Wind Power Group Limited designs, manufactures, sells, and services megawatt-class wind turbines in the People’s Republic of China. The company provides wind turbines with a rated power capacity of 1.5MW and 2.0MW; 2.5/3.0MW SCD; and 6.0/6.5MW SCD wind turbines. It also manufactures and sells wind turbine blades and components; and leases wind turbines. In addition, the company is involved in the research and development of wind turbine technology; maintenance operations; investment and financing activities; and operation of a wind farm.
At the end of Wednesday’s trade, Prima Biomed Ltd. (NASDAQ:PBMD)‘s shares dipped -7.41% to $2.75.
Editors and readers are advised to disregard the duplicate news release with the headline, “CVac Shows Clear Trend for Overall Survival Benefit in Second Remission Ovarian Cancer in Phase II Study,” that was distributed on May 26, 2015 and sourced to Prima Biomed Ltd. (PBMD). The release was formerly declared on May 19, 2015 and was re-issued in error instead of this intended declarement, through the fault of PCG Advisory Group.
On May 25, 2015, Prima declared on the ASX that it has reached a contract with the US-based Database Integrations Inc. (DBI) for the two companies to commercialise iCAN, the software platform that powers Prima’s CVac cellular therapy, for use in other cellular therapies worldwide.
iCAN, which was designed by DBI to Prima’s specifications and commissioned in 2011, handles, in a scalable architecture and with a high level of automation, all the electronic records and electronic signatures associated with labelling, manufacturing operations, distribution, logistics, communications and scheduling for immuno-cellular therapies like CVac. With iCAN having significantly contributed to making CVac an efficient and relatively low cost cellular therapy in the years since 2011, Prima and DBI believe that other developers of cellular therapies will benefit from iCAN with their products. Under the Agreement being declared recently the two companies will work together to seek sub-licensees for that system. It is envisaged that Prima will earn a percentage of the revenues that Database Integrations earns from new sub-licensees.
Prima BioMed Ltd. researches, develops, and commercializes medical biotechnology products in Australia. The company develops immunocellular therapeutic products for the treatment of cancer. Its lead product is CVac, an autologous dendritic cell-based product presently in clinical trials for ovarian and pancreatic cancer patients. Prima BioMed Ltd. is based in Sydney, Australia.
AEterna Zentaris Inc. (USA) (NASDAQ:AEZS), ended its Wednesday’s trading session with -6.78% loss, and closed at $0.275.
AEterna Zentaris Inc. (USA) (AEZS) declared that it has received written scientific advice from the European Medicines Agency (“EMA”) regarding the further development plan, counting the study design, for the new confirmatory Phase 3 clinical study of Macrilen™ (macimorelin) for use in evaluating adult growth hormone deficiency (“AGHD”), following a Scientific Advice Meeting that was held earlier this month. As a result of the advice, the Company believes that the confirmatory Phase 3 study that was talk abouted with the U.S. Food & Drug Administration (“FDA”) last March, meets the EMA’s study-design expectations.
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women’s health. The companys product pipeline comprises MACRILEN, which accomplished the Phase 2 trial for use in the diagnosis of adult growth hormone deficiency; and zoptarelin doxorubicin, which is in Phase 3 clinical study zoptarelin doxorubicin in endometrial cancer (ZoptEC) of the compound in women with advanced, recurrent, or metastatic endometrial cancer.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
